Childhood Rhabdomyosarcoma: New Insight on Biology and Treatment (Q37785820)

23 August 2017

title

Childhood rhabdomyosarcoma: new insight on biology and treatment (English)

1 reference

23 August 2017

Childhood Rhabdomyosarcoma: New Insight on Biology and Treatment (English)

1 reference

https://api.crossref.org/works/10.1007/S11912-010-0130-3

Childhood Rhabdomyosarcoma

7 July 2024

main subject

1 reference

Winston W. Huh

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20820958

7 July 2024

Stephen X. Skapek

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20820958

7 July 2024

publication date

1 November 2010

1 reference

23 August 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20820958

http://www.current-reports.com/1523-3790/12/402

7 July 2024

work available at URL

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20820958

http://link.springer.com/content/pdf/10.1007/s11912-010-0130-3.pdf

7 July 2024

1 reference

https://api.crossref.org/works/10.1007/S11912-010-0130-3

http://link.springer.com/article/10.1007/s11912-010-0130-3/fulltext.html

7 July 2024

1 reference

https://api.crossref.org/works/10.1007/S11912-010-0130-3

http://link.springer.com/content/pdf/10.1007/s11912-010-0130-3

7 July 2024

1 reference

https://api.crossref.org/works/10.1007/S11912-010-0130-3

7 July 2024

published in

Current Oncology Reports

1 reference

23 August 2017

volume

12

1 reference

23 August 2017

issue

6

1 reference

23 August 2017

page(s)

402-410

1 reference

Trends in childhood rhabdomyosarcoma incidence and survival in the United States, 1975-2005

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11912-010-0130-3

PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-010-0130-3

Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-010-0130-3

Neurofibromatosis in children with Rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma study IV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-010-0130-3

Prenatal X-ray exposure and rhabdomyosarcoma in children: a report from the children's oncology group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-010-0130-3

Birth characteristics and the risk of childhood rhabdomyosarcoma based on histological subtype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-010-0130-3

Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of intergroup rhabdomyosarcoma study group experience and rationale for Intergroup Rhabdomyosarcoma Study V.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-010-0130-3

Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children's Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-010-0130-3

Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-010-0130-3

Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groups.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-010-0130-3

Sequential high-dose chemotherapy for children with metastatic rhabdomyosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-010-0130-3

Treatment of children with metastatic soft tissue sarcoma with oral maintenance compared to high dose chemotherapy: report of the HD CWS-96 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-010-0130-3

Outcomes in paediatric metastatic rhabdomyosarcoma: Results of The International Society of Paediatric Oncology (SIOP) study MMT-98

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-010-0130-3

Cooperative trial CWS-91 for localized soft tissue sarcoma in children, adolescents, and young adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-010-0130-3

Prevalence and clinical impact of anaplasia in childhood rhabdomyosarcoma : a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-010-0130-3

Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-010-0130-3

Gene expression profiling for survival prediction in pediatric rhabdomyosarcomas: a report from the children's oncology group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-010-0130-3

Prognostic significance of tumor response at the end of therapy in group III rhabdomyosarcoma: a report from the children's oncology group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-010-0130-3

Comparison of the prognostic value of assessing tumor diameter versus tumor volume at diagnosis or in response to initial chemotherapy in rhabdomyosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-010-0130-3

Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-010-0130-3

Hypoxia enhances tumor stemness by increasing the invasive and tumorigenic side population fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-010-0130-3

Alveolar rhabdomyosarcoma: is the cell of origin a mesenchymal stem cell?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-010-0130-3

Cellular and molecular signatures of muscle regeneration: current concepts and controversies in adult myogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-010-0130-3

PAX7 expression in embryonal rhabdomyosarcoma suggests an origin in muscle satellite cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-010-0130-3

Alveolar rhabdomyosarcomas in conditional Pax3:Fkhr mice: cooperativity of Ink4a/ARF and Trp53 loss of function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-010-0130-3

Mrf4 determines skeletal muscle identity in Myf5:Myod double-mutant mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-010-0130-3

Mutation and expression analyses of the MET and CDKN2A genes in rhabdomyosarcoma with emphasis on MET overexpression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-010-0130-3

Molecular classification of rhabdomyosarcoma--genotypic and phenotypic determinants of diagnosis: a report from the Children's Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-010-0130-3

Molecular and cellular biology of rhabdomyosarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-010-0130-3

Expression of insulin-like growth factor pathway proteins in rhabdomyosarcoma: IGF-2 expression is associated with translocation-negative tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-010-0130-3

Genomic imbalances in rhabdomyosarcoma cell lines affect expression of genes frequently altered in primary tumors: an approach to identify candidate genes involved in tumor development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-010-0130-3

RAS signaling dysregulation in human embryonal Rhabdomyosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-010-0130-3

Genomic and clinical analyses of 2p24 and 12q13-q14 amplification in alveolar rhabdomyosarcoma: a report from the Children's Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-010-0130-3

Identification of a PAX-FKHR gene expression signature that defines molecular classes and determines the prognosis of alveolar rhabdomyosarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-010-0130-3

The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-010-0130-3

The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-010-0130-3

Phosphoprotein pathway mapping: Akt/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-010-0130-3

Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-010-0130-3

Synergism between INK4a/ARF inactivation and aberrant HGF/SF signaling in rhabdomyosarcomagenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-010-0130-3

A Drosophila model of the rhabdomyosarcoma initiator PAX7-FKHR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-010-0130-3

Effects of RAS on the genesis of embryonal rhabdomyosarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-010-0130-3

Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models

21 January 2018

1 reference

12 December 2020

Genetic modeling of human rhabdomyosarcoma

1 reference

12 December 2020

Assessment of response to induction therapy and its influence on 5-year failure-free survival in group III rhabdomyosarcoma: the Intergroup Rhabdomyosarcoma Study-IV experience--a report from the Soft Tissue Sarcoma Committee of the Children's Oncol

1 reference

12 December 2020

Recurrent t(2;2) and t(2;8) translocations in rhabdomyosarcoma without the canonical PAX-FOXO1 fuse PAX3 to members of the nuclear receptor transcriptional coactivator family

1 reference

12 December 2020

Mouse mesenchymal stem cells expressing PAX-FKHR form alveolar rhabdomyosarcomas by cooperating with secondary mutations

1 reference

12 December 2020

Dedifferentiation of mammalian myotubes induced by msx1

1 reference

12 December 2020

Accuracy of 18F fluorodeoxyglucose positron emission tomography/computed tomography in staging of pediatric sarcomas

1 reference

12 December 2020

Metastatic rhabdomyosarcoma cured after chemotherapy and allogeneic SCT

1 reference

12 December 2020

Journal of Clinical Investigation

43

119

3395

JG Taylor

2009

1 reference

https://api.crossref.org/works/10.1007/S11912-010-0130-3

7 July 2024

Identifiers

1 reference

23 August 2017

1 reference